PLGA-PEG-COOH from PolySciTech used in development of ultra-sound triggered breast cancer theranostic nanoparticles

One of the goals within controlled delivery is to provide for targeted medicinal delivery in which the medicine is guided to the site that it is needed in by natural processes. More specifically, in cancer, there is a need to delivery nanoparticles to the tumor site for both therapy (medicinal delivery) as well as diagnosis (contrast agent delivery) Recently, researchers at Chongqing Medical University (China) used PolySciTech (www.polyscitech.com) product PLGA-PEG-COOH (PolyVivo AI056) and conjugated on Herceptin (antibody which conjugates to breast cancer tumors) to target it towards breast cancer cells. They formulated these with both contrast agents and chemotherapeutic paclitaxel. This research holds promise for improved breast-cancer therapy. Read more: Song, Weixiang, Yindeng Luo, Yajing Zhao, Xinjie Liu, Jiannong Zhao, Jie Luo, Qunxia Zhang, Haitao Ran, Zhigang Wang, and Dajing Guo. "Magnetic nanobubbles with potential for targeted drug delivery and trimodal imaging in breast cancer: an in vitro study." Nanomedicine 0 (2017). http://www.futuremedicine.com/doi/abs/10.2217/nnm-2017-0027

“Aim: The aim of this study was to improve tumor-targeted therapy for breast cancer by designing magnetic nanobubbles with the potential for targeted drug delivery and multimodal imaging. Materials & methods: Herceptin-decorated and ultrasmall superparamagnetic iron oxide (USPIO)/paclitaxel (PTX)-embedded nanobubbles (PTX-USPIO-HER-NBs) were manufactured by combining a modified double-emulsion evaporation process with carbodiimide technique. PTX-USPIO-HER-NBs were examined for characterization, specific cell-targeting ability and multimodal imaging. Results: PTX-USPIO-HER-NBs exhibited excellent entrapment efficiency of Herceptin/PTX/USPIO and showed greater cytotoxic effects than other delivery platforms. Low-frequency ultrasound triggered accelerated PTX release. Moreover, the magnetic nanobubbles were able to enhance ultrasound, magnetic resonance and photoacoustics trimodal imaging. Conclusion: These results suggest that PTX-USPIO-HER-NBs have potential as a multimodal contrast agent and as a system for ultrasound-triggered drug release in breast cancer.”